EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform

Suleman Khan Zadran iD, Nicola Facchinello, Piergiuseppe De Rosa, Roberto Saporetti, Paolo Emidio Costantini, Luca Ulfo, Michela Nigro, Annapaola Petrosino, Lucia Pappagallo, Sara Aloisi, Giorgio Milazzo, Zainul Abe Din und 14 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202415356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Suleman Khan Zadran und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Biotechnology Alma Mater Studiorum - University of Bologna, via Francesco Selmi 3, Bologna, 40126, Italy. Hauptthemen laut MEDLINE: Neuroblastoma, Gangliosides, Bacteriophages, Oncolytic Virotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research, European Union, NextGenerationEU, PRIN2022 Prot..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disialoganglioside‐GD2 is a key molecular target for Neuroblastoma (NB) immunotherapy based on the employment of GD2‐targeting antibodies. However, about 50% of treated patients can experience tumor relapse due to limited immune‐mediated cytotoxicity and poor antibody penetration into tumors. To address this problem, a tumor‐penetrating photo‐oncolytic phage nanovector platform is genetically and chemically developed that selectively targets GD2‐expressing NB cells. The phage bioconjugates, functionalized with different photosensitizers, result in specific and selective oncolysis of GD2‐positive NB cells upon light irradiation, without affecting GD2‐negative ones. The photo‐oncolytic phage vectors are shown to deeply penetrate into GD2‐positive tumor spheroids in vitro, and to cross biological barriers in a zebrafish xenograft model, maintaining their ablation specificity upon irradiation. Finally, to overcome resistance from GD2 loss, often linked to poor prognosis, a CRISPRa strategy is introduced to reactivate GD2 expression in GD2‐negative cells. The approach offers a minimally invasive and highly effective strategy, addressing unmet needs in NB therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaGangliosidesBacteriophagesOncolytic VirotherapyHumansAnimalsZebrafishCell Line, TumorPhotochemotherapyPhotosensitizing Agents

Stichwörter der Autor:innen

CRISPRaM13 bacteriophage biotherapeuticsneuroblastoma GD2photodynamic therapyzebrafish xenograft

Substanzen

Gangliosidesganglioside, GD2sialogangliosidesPhotosensitizing Agents

Autor:innen und Institutionen

  • Department of Pharmacy and Biotechnology Alma Mater Studiorum - University of Bologna, via Francesco Selmi 3, Bologna, 40126, Italy.
  • Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) AOUBO Sant Orsola - Laboratory of Preclinical and Translational Research in Oncology (PRO), Bologna, 40138, Italy.
  • Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna, Programma di Neurogenetica, Bologna, 40139, Italy.
  • Department of Chemistry "Giacomo Ciamician", Alma Mater Studiorum - University of Bologna, Via Francesco Selmi 2, Bologna, 40126, Italy.
  • Institute for Organic Synthesis and Photoreactivity (ISOF), National Research Council of Italy (CNR), Via P. Gobetti 101, Bologna, I-40129, Italy.

ORCID-Profile: Suleman Khan Zadran, Matteo Calvaresi, Giovanni Perini

Förderung

  • Italian Ministry of University and Research
  • European Union, NextGenerationEU
  • PRIN2022 Prot.
  • Associazione Italiana per la Ricerca sul Cancro
  • Associazione Italiana per la Ricerca sul Cacro

Zitieren

APA

Zadran, S. K., Facchinello, N., De Rosa, P., Saporetti, R., Costantini, P. E., Ulfo, L., Nigro, M., Petrosino, A., Pappagallo, L., Aloisi, S., Milazzo, G., Din, Z. A., Rigamonti, A., Flora, L., Santulli, M., Cimadom, L., Zuccheri, G., Zangoli, M., Sante, M. D., …, & Perini, G. (2025). Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform. Advanced Science. https://doi.org/10.1002/advs.202415356

Vancouver

Zadran SK, Facchinello N, De Rosa P, Saporetti R, Costantini PE, Ulfo L, et al. Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform. Advanced Science. 2025. doi:10.1002/advs.202415356

BibTeX
@article{Zadran2025,
  author = {Zadran, Suleman Khan and Facchinello, Nicola and De Rosa, Piergiuseppe and Saporetti, Roberto and Costantini, Paolo Emidio and Ulfo, Luca and Nigro, Michela and Petrosino, Annapaola and Pappagallo, Lucia and Aloisi, Sara and Milazzo, Giorgio and Din, Zainul Abe and Rigamonti, Alberto and Flora, Leonardo and Santulli, Martina and Cimadom, Leonardo and Zuccheri, Giampaolo and Zangoli, Mattia and Sante, Manuele Di and Giosia, Matteo Di and Maria, Francesca Di and Bernardoni, Roberto and Barbieri, Eveline and Calvaresi, Matteo and Danielli, Alberto and Perini, Giovanni},
  title = {Systematic Targeting of GD2‐Positive Neuroblastoma Tumors With a Photooncolytic Phage Nanovector Platform},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202415356}
}
Kostenlos starten →